NVO
Novo Nordisk A/S
NVO has a slight edge over YARW overall, supported by lower modeled downside and stronger fundamentals.
YARW
Yarrow Bioscience Inc
YARW offers stronger modeled upside, but that advantage does not outweigh its weaker overall profile.
NVO Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Stable | |
| Healthy |
NVO's revenue, profitability and balance sheet are currently healthy, and its cash flow is stable.
YARW Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Under pressure | |
| Weak | |
| Unavailable |
YARW's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
NVO PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 10x | $40.65 | — |
| Cheap | 14x | $53.56 | +32% |
| Fair | 27x | $103 | +154% |
| Expensive | 39x | $152 | +273% |
Historical ranges are pointers, not guarantees.
NVO's PE is 10x, but its earnings don't support one, so it isn't a reliable read right now.
YARW PE Valuation
YARW has no meaningful PE right now: it lost money over the past year.
NVO Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Stable | |
| Growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect NVO's revenue to grow, but its profitability to weaken. However, they disagree widely on these estimates.
YARW Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong decline | |
| -- | |
| Limited | |
| High |
Analysts expect YARW's losses to shrink, with revenue declining.
NVO Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | $3.89 | +4.9% |
| Q1 2026 | $4.07 | +17% |
| Q4 2025 | $3.42 | +1.8% |
| Q3 2025 | $3.47 | +10% |
| Q2 2025 | $3.71 | +24% |
| Q1 2025 | $3.49 | +18% |
| Q4 2024 | $3.36 | +21% |
| Q3 2024 | $3.15 | +27% |
NVO has the edge over YARW on earnings quality, reporting a profit while its opponent remains loss making.
YARW Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$23.27 | +$21.23 |
| Q1 2026 | -$26.26 | +$22.74 |
| Q4 2025 | -$32.26 | +$14.24 |
| Q3 2023 | -$498.97 | -$111.97 |
| Q2 2023 | -$542.47 | +$69.53 |
| Q1 2023 | -$522.97 | +$305.03 |
| Q4 2022 | -$363.97 | +$914.03 |
| Q3 2022 | -$387.00 | +$216.00 |
YARW lost $23.27 per share over the past year, a smaller loss than the year before.
NVO Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $11.7B | +2.1% |
| Q1 2026 | $14.4B | +24% |
| Q4 2025 | $11.8B | -7.6% |
| Q3 2025 | $11.1B | +5.1% |
| Q2 2025 | $11.4B | +13% |
| Q1 2025 | $11.6B | +19% |
| Q4 2024 | $12.7B | +30% |
| Q3 2024 | $10.6B | +21% |
NVO's revenue is growing: $11.7B last quarter, up 2.1% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 34% | -9 points |
| Q1 2026 | 62% | +12 points |
| Q4 2025 | 40% | -2.8 points |
| Q3 2025 | 32% | -16 points |
| Q2 2025 | 44% | +5.4 points |
| Q1 2025 | 50% | +1 points |
| Q4 2024 | 43% | +2.2 points |
| Q3 2024 | 47% | +1.6 points |
NVO has the edge over YARW on profitability, with a higher operating margin.
YARW Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $97K | +41% |
| Q1 2026 | $86K | -57% |
| Q4 2025 | $130K | +55% |
| Q3 2025 | $169K | +40% |
| Q2 2025 | $69K | -65% |
| Q1 2025 | $202K | +106% |
| Q4 2024 | $84K | +11% |
| Q3 2024 | $121K | +6.1% |
YARW's revenue is recovering but still below its 2020 peak: $97,000 last quarter, up 41% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -3198% | +7733 points |
| Q1 2026 | -4437% | +116 points |
| Q4 2025 | -4015% | +11188 points |
| Q3 2025 | -4611% | +6208 points |
| Q2 2025 | -10930% | -5680 points |
| Q1 2025 | -4553% | +2978 points |
| Q4 2024 | -15202% | -6213 points |
| Q3 2024 | -10819% | -5351 points |
YARW's operating margin was −3198% last quarter, up 7732 points from the same quarter a year ago.
NVO Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $6.3B | +73% |
| Q1 2026 | $1.8B | +20% |
| Q4 2025 | -$5.4B | -$4.7B |
| Q3 2025 | $4.6B | -2.1% |
| Q2 2025 | $3.6B | -34% |
| Q1 2025 | $1.5B | +89% |
| Q4 2024 | -$632.6M | +$390.5M |
| Q3 2024 | $4.7B | +3.3% |
NVO has the edge over YARW on cash generation, producing positive trailing cash flow while its opponent burns cash.
YARW Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$2M | +$8.8M |
| Q1 2026 | -$4.1M | +$7.4M |
| Q3 2025 | -$7.1M | +$1.4M |
| Q2 2025 | -$10.8M | -$2.3M |
| Q1 2025 | -$11.5M | -$3.5M |
| Q3 2024 | -$8.5M | -$3.4M |
| Q2 2024 | -$8.5M | +$1.1M |
| Q1 2024 | -$8M | -$2.5M |
YARW has burned cash in almost every quarter: −$17M over the past year, against −$39M the year before.
NVO Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.3% | -12.9M shares |
| 1 year | -0.2% | -11M shares |
| 3 years | -1.5% | -66.8M shares |
| 5 years | -3.8% | -177M shares |
| Available history | -6.5% | -311M shares |
NVO has the edge over YARW on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $520M |
| Q1 2026 | $356.7M |
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | $206.3M |
| Q4 2024 | $1.1B |
| Q3 2024 | $357.4M |
NVO spent $877M buying back its own shares over the past year, down 48% from the year before.
YARW Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +2.6K shares |
| 1 year | +0.3% | +2.8K shares |
| 3 years | +1247% | +794K shares |
| 5 years | +1741% | +811K shares |
| Available history | +12794% | +851K shares |
YARW has 858,000 diluted shares, about the same as a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | $15,000 |
| Q3 2025 | $7,000 |
NVO Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | 0.5x | Very low |
| Q1 2026 | 0.7x | Very low |
| Q4 2025 | 0.6x | Very low |
| Q3 2025 | 0.4x | Very low |
| Q2 2025 | 0.5x | Very low |
| Q1 2025 | 0.5x | Very low |
| Q4 2024 | 0.6x | Very low |
| Q3 2024 | -0.0x | Very low |
NVO's net debt is less than a year of its operating earnings (EBITDA).
YARW Net Leverage
YARW's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
NVO Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.0 | Neutral |
| Stochastic | 27.0 | Neutral |
NVO's weekly RSI is 43 (neutral) and its Stochastic is 27 (neutral).
YARW Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 40.5 | Neutral |
| Stochastic | 13.3 | Oversold |
YARW's weekly RSI is 40 (neutral) and its Stochastic is 13 (oversold).
NVO PE vs Healthcare Sector
| Metric | NVO | Sector median | Relative |
|---|---|---|---|
| PE | 10x | 26x | 60% below |
| PE % | 6 | 29 | 23 pts below |
NVO is trading at 10x earnings, a 60% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
YARW PE vs Healthcare Sector
YARW has no meaningful PE right now: it lost money over the past year.
NVO Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $39.2 | 3.7% above |
| 20 week MA | $43.9 | 7.4% below |
| 50 week MA | $45.3 | 10% below |
| 100 week MA | $56.3 | 28% below |
| 200 week MA | $80.7 | 50% below |
NVO has the edge over YARW on trend strength, trading above more of its moving averages.
YARW Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $20.0 | 2% below |
| 20 week MA | $28.4 | 31% below |
| 50 week MA | $29.3 | 33% below |
| 100 week MA | $47.7 | 59% below |
| 200 week MA | $102.9 | 81% below |
YARW is in a downtrend: it's below all five of its weekly moving averages, and 81% below its 200-week average.
NVO Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $29.1 | $34.7 | +19% |
| 2021 | $34.7 | $54.2 | +56% |
| 2022 | $54.2 | $67.0 | +24% |
| 2023 | $67.0 | $103.5 | +54% |
| 2024 | $103.5 | $87.4 | -16% |
| 2025 | $87.4 | $52.4 | -40% |
| 2026 YTD | $52.4 | $40.7 | -22% |
NVO has the edge over YARW on returns for 2026, with the stronger performance.
YARW Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $18,000.0 | $6,372.0 | -65% |
| 2021 | $6,372.0 | $1,008.0 | -84% |
| 2022 | $1,008.0 | $107.0 | -89% |
| 2023 | $107.0 | $116.5 | +8.9% |
| 2024 | $116.5 | $158.5 | +36% |
| 2025 | $158.5 | $29.4 | -81% |
| 2026 YTD | $29.4 | $19.6 | -33% |
YARW has finished lower in four of the last six years. It's down 33% so far in 2026.